List view / Grid view

Natalia Elizalde (VIVEbiotech)

 

article

The rising demand for lentiviral vectors for in vivo gene therapy

Fuelled by advances in rare disease treatments and vaccination efforts,…

6 September 2024 | By

Fuelled by advances in rare disease treatments and vaccination efforts, Natalia Elizalde, CBO at VIVEbiotech, discusses how the market demand for lentiviral vectors is evolving, the new therapeutic areas emerging as potential targets for in vivo gene therapy and the latest technological advancements in the development and delivery of in…